Comparing liposomal bupivacaine and ropivacaine for pain relief after abdominal surgery
Liposomal Bupivacaine vs Ropivacaine for Ultrasound-guided Transversus Abdominis Plane Blocks in Laparoscopic Lower Abdominal Tumor Resection: A Prospective Randomized Trial
This study is testing whether liposomal bupivacaine or ropivacaine can help reduce pain and the need for opioids after abdominal surgery for patients having tumor resections.
Quick facts
| Phase | Phase 3 |
|---|---|
| Study type | Interventional |
| Enrollment | 74 (estimated) |
| Ages | 18 Years to 70 Years |
| Sex | All |
| Sponsor | Sun Yat-sen University Academic / other |
| Locations | 1 site (Guangzhou, Guangdong) |
| Trial ID | NCT06430112 on ClinicalTrials.gov |
What this trial studies
This clinical trial investigates the effectiveness of liposomal bupivacaine versus ropivacaine in reducing postoperative opioid consumption for patients undergoing laparoscopic lower abdominal tumor resections. A total of 76 patients will be randomly assigned to receive either liposomal bupivacaine or ropivacaine through ultrasound-guided transversus abdominis plane blocks. Pain scores and opioid usage will be monitored at various intervals post-surgery, along with any adverse effects experienced by the patients. The goal is to determine which anesthetic provides better pain management and reduces the need for opioids after surgery.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18-70 with ASA grade II-III who are scheduled for laparoscopic resection of lower abdominal tumors.
Not a fit: Patients with a history of opioid tolerance, allergies to local anesthetics, or serious comorbid conditions may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved pain management strategies and reduced opioid use for patients undergoing abdominal surgeries.
How similar studies have performed: Previous studies have shown varying results in the efficacy of liposomal bupivacaine compared to traditional anesthetics, making this approach both relevant and potentially novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Patients undergoing laparoscopic resection of lower abdominal tumors 2. ASA grade II-III 3. Age: 18-70 years. Exclusion Criteria: 1. (1) The patient does not agree to participate in the clinical study 2. (2) The patient has a clear history of opioid tolerance or allergy 3. (3) The patient has a history of local anesthetic allergy 4. (4) Previous history of dementia, mental illness or other central nervous system diseases 5. (5) Have a history of chronic pain or are taking opioids and other analgesics 6. (6) Patients are generally in poor condition with a history of serious diseases of cardiovascular system, respiratory system, digestive system, urinary system or central nervous system, and may not survive for more than 3 months 7. (7) The patient had any of the following conditions in the 12 months before surgery: myocardial infarction, severe/unstable angina pectoris, coronary artery bypass grafting, congestive heart failure, cerebrovascular accident, pulmonary embolism 8. (8) Pregnant women 9. (9) Unable to cooperate with follow-up or poor compliance 10. (10) Patients with acute myocardial infarction, cardiac arrest or shock during surgery or hospitalization 11. (11) ASA score above grade III.
Where this trial is running
Guangzhou, Guangdong
- Jingdun Xie — Guangzhou, Guangdong, China (Recruiting)
Study contacts
- Principal investigator: Jingdun Xie — Department of Anesthesiology,Sun Yat-Sen University Cancer Center
- Study coordinator: Ping Yu
- Email: yuping@sysucc.org.cn
- Phone: 00-86-13631373286
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.